Tomoya Fukui

8PUBLICATIONS
33CO-AUTHORS
Epidemiological modellingPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 27, 2026
Predictors of Pre- and Postoperative Quality of Life and Overall Survival in Patients with Non-Small Cell Lung Cancer: A Prospective Study.

Ryuta Fukai, Tomoki Nishida, Nobuo Yamaguchi

|Jul 10, 2025
Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1-Expressing Non-Small Cell Lung Cancer.

Tae Hata, Tadaaki Yamada, Yasuhiro Goto

|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.

Shiho Goda, Tadaaki Yamada, Kenji Morimoto

|Sep 20, 2024
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.

Makoto Hibino, Yoshinori Imamura, Rai Shimoyama

|Dec 15, 2022
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).

Tomoya Fukui, Jiichiro Sasaki, Satoshi Igawa

|Feb 15, 2020
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.

Tomoya Fukui, Shinji Hosotani, Itaru Soda

Pageof 2

Frequent Collaborators

4 joint publications

Makoto Hibino

3 joint publications

Satoshi Igawa

2 joint publications

Yoshiki Negi

2 joint publications

Ryuta Fukai